Abstract
Alzheimers disease is characterized by the presence of two types of lesions in brain: neurofibrillary tangles and senile plaques. Intraneuronal neurofibrillary tangles are made of paired helical filaments containing hyperphosphorylated microtubule associated protein tau. Extracellular senile plaques contain a core of beta-amyloid peptide (Aβ), which is produced by cleavage of the Amyloid Precursor Protein (APP). Among the two catabolic pathways of APP, the amyloidogenic pathway producing Aβ peptides was intensively studied in different cellular models expressing human APP. Differences in APP processing and in toxicity resulting from Aβ accumulation can be observed from one cell type to another. In particular, primary cultures of neurons process APP differently compared with other cultured cells including neuronal cell lines. Neurons accumulate intraneuronal Aβ, which is neurotoxic, and in these cells, APP can be phosphorylated at specific residues. Recent studies suggest that APP phosphorylation can play an important role in its amyloidogenic processing. In addition, protein kinases that phosphorylate APP are also able to phosphorylate the neuronal protein tau. Biochemical analysis of these two proteins in primary cultures of neurons show that phosphorylation of both APP and tau can be a factor linking the two characteristic lesions of Alzheimers disease.
Keywords: Alzheimer's disease, APP, processing, amyloid peptide, neuron, cell lines, toxicity, tau, phosphorylation
Current Alzheimer Research
Title: Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Volume: 5 Issue: 2
Author(s): Pierrot Nathalie and Octave Jean-Noel
Affiliation:
Keywords: Alzheimer's disease, APP, processing, amyloid peptide, neuron, cell lines, toxicity, tau, phosphorylation
Abstract: Alzheimers disease is characterized by the presence of two types of lesions in brain: neurofibrillary tangles and senile plaques. Intraneuronal neurofibrillary tangles are made of paired helical filaments containing hyperphosphorylated microtubule associated protein tau. Extracellular senile plaques contain a core of beta-amyloid peptide (Aβ), which is produced by cleavage of the Amyloid Precursor Protein (APP). Among the two catabolic pathways of APP, the amyloidogenic pathway producing Aβ peptides was intensively studied in different cellular models expressing human APP. Differences in APP processing and in toxicity resulting from Aβ accumulation can be observed from one cell type to another. In particular, primary cultures of neurons process APP differently compared with other cultured cells including neuronal cell lines. Neurons accumulate intraneuronal Aβ, which is neurotoxic, and in these cells, APP can be phosphorylated at specific residues. Recent studies suggest that APP phosphorylation can play an important role in its amyloidogenic processing. In addition, protein kinases that phosphorylate APP are also able to phosphorylate the neuronal protein tau. Biochemical analysis of these two proteins in primary cultures of neurons show that phosphorylation of both APP and tau can be a factor linking the two characteristic lesions of Alzheimers disease.
Export Options
About this article
Cite this article as:
Nathalie Pierrot and Jean-Noel Octave, Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity, Current Alzheimer Research 2008; 5 (2) . https://dx.doi.org/10.2174/156720508783954721
DOI https://dx.doi.org/10.2174/156720508783954721 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Amyloidophilic Compounds for Prion Diseases
Infectious Disorders - Drug Targets Recent Advances of Metallocenes for Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Current Drug Targets From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Cell Contact/Adhesion Proteins Lgl and DFak56: Tumorigenic and Whole-Organism Vital Effects Studied in Drosophila
Anti-Cancer Agents in Medicinal Chemistry Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine